Moore TJ, Mattison DR. Assessment of patterns of potentially unsafe use of zolpidem. JAMA Intern Med 2018;178:septiembre. [Ref.ID 102884]

Pérez T, Moriarty F, Wallace E, McDowell R, Redmond P, Fahey T. Prevalence of potentially inappropriate prescribing in older people in primary care and its association with hospital admission: longitudinal study. BMJ 2018;363:14 de noviembre. [Ref.ID 102868]

Angus-Leppan H, Liu RSN. Weighing the risks of valproate in women who could become pregnant. BMJ 2018;361:18 de abril. [Ref.ID 102682]

Bielecka-Dabrowa A, Fabis J, Mikhailidis DP, von Haehling S, Sahebkar A, Rysz J, Banach M. Prosarcopenic effects of statins may limit their effectiveness in patients with heart failure. Trends Pharmacol Sci 2018;39:abril. [Ref.ID 102681]

Anónimo. Saccharomyces boulardii probiotics: Do not use in critically ill or immunocompromised patients. Estonia . WHO Drug Information 2018;32:19. [Ref.ID 102623]

Iacobucci G. MHRA bans valproate prescribing for women not in pregnancy prevention programme. BMJ 2018;361:k1823. [Ref.ID 102614]

Hirschler B. UK bans Sanofi epilepsy drug without pregnancy prevention plan. Reuters Health News 2018:24 de abril. [Ref.ID 102553]

Anónimo. Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone. European Medical Agency 2018:1. [Ref.ID 102552]

Anónimo. Clarithromycin (Biaxin): Drug safety communication - Potential increased risk of heart problems or death in patients with heart disease. FDA U.S. Food and Drug Administration 2018:22 de febrero. [Ref.ID 102539]

Orlova Y, Rizzoli P, Loder E. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurology 2018;75:566-72. [Ref.ID 102536]

Herzig SJ, Mosher HJ, Calcaterra SL, Jena AB, Nuckols TK. Improving the safety of opioid use for acute noncancer pain in hospitalized adults: a consensus statement from the Society of Hospital Medicine. J Hosp Med 2018;13:abril. [Ref.ID 102501]

Varga S, Alcusky M, Keith SW, Hegarty SE, Del Canale S, Lombardi M, Maio V. Hospitalization rates during potentially inappropriate medication use in a large population-based cohort of older adults. Br J Clin Pharmacol 2017;83:2572-80. [Ref.ID 102117]

Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, Ratner R, Barrett-Connor E, Temprosa M, on behalf of the Diabetes Prevention Program(DPP) Research Group. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program.. BMJ Open Diabetes Research & Care 2017;5:1-10. [Ref.ID 102101]

Castellsague J, Perez-Gutthann S, Calingaert B, Bui C, Varas-Lorenzo C, Arana A, Prados-Torres A, Poblador-Plou B, Gonzlez-Rubio F, Giner-Soriano M, Roso-Llorach A, Linder M, Citarella A, Scholle O, Blenk T, Garbe E. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiol Drug Saf 2017;26:615-24. [Ref.ID 101961]

Anónimo. Beta blockers and the risk of CV events in type 2 diabetes. Diabetes in Control 2017:29 de julio. [Ref.ID 101936]

Lee SWH, Lai NM, Chaiyakunapruk N, Chong DWK. Adverse effects of herbal or dietary supplements in G6PD deficiency: a systematic review. Br J Clin Pharmacol 2017;83:172-9. [Ref.ID 101929]

Chan FK, Leung KE, Wong GL, Ching JY, Tse YK, Au KW, Wu JC, Nq SC. Risks of bleeding recurrence and cardiovascular events with continued aspirin use after lower gastrointestinal hemorrhage. Gastroenterology 2016;151:271-7. [Ref.ID 100594]

Finch A, Kubler P. The management of gout. Australian Prescriber 2016;39:1 de agosto. [Ref.ID 100572]

Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]

Anónimo. Riociguat (Adempas): contraindicado en pacientes con hipertensión pulmonar asociada a neumonías intersticiales idiopáticas (HP-NII). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2016:27 de junio. [Ref.ID 100441]